156 related articles for article (PubMed ID: 29353436)
21. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
23. Time to adjuvant therapy and other variables in localized gastric and gastroesophageal junction (GEJ) cancer (IJGC-D-13-00162).
Ahmed S; Iqbal N; Yadav S; Zaidi A; Ahmed O; Alvi R; Gardner D; Haider K
J Gastrointest Cancer; 2014 Sep; 45(3):284-90. PubMed ID: 24493115
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
[TBL] [Abstract][Full Text] [Related]
25. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
26. Variation in palliative care of esophageal cancer in clinical practice: factors associated with treatment decisions.
Opstelten JL; de Wijkerslooth LR; Leenders M; Bac DJ; Brink MA; Loffeld BC; Meijnen-Bult MJ; Minderhoud IM; Verhagen MA; van Oijen MG; Siersema PD
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26919349
[TBL] [Abstract][Full Text] [Related]
27. The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers.
Mariette C; Renaud F; Piessen G; Gele P; Copin MC; Leteurtre E; Delaeter C; Dib M; Clisant S; Harter V; Bonnetain F; Duhamel A; Christophe V; Adenis A;
BMC Cancer; 2018 Feb; 18(1):139. PubMed ID: 29409462
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
[TBL] [Abstract][Full Text] [Related]
29. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
30. Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis.
Li Y; Huang HC; Chen LQ; Xu LY; Li EM; Zhang JJ
Surg Oncol; 2017 Dec; 26(4):460-472. PubMed ID: 29113666
[TBL] [Abstract][Full Text] [Related]
31. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
32. Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma.
Grenader T; Plotkin Y; Mohammadi B; Dawas K; Hashemi M; Mughal M; Bridgewater JA
J Gastrointest Cancer; 2015 Sep; 46(3):267-71. PubMed ID: 25952408
[TBL] [Abstract][Full Text] [Related]
33. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
34. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer.
van Velzen MJM; Pape M; Dijksterhuis WPM; Slingerland M; van Voorthuizen T; Beerepoot LV; Creemers GJ; Derks S; Mohammad NH; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2021 Oct; 156():60-69. PubMed ID: 34425405
[TBL] [Abstract][Full Text] [Related]
35. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.
Sartore-Bianchi A; Amatu A; Bonazzina E; Stabile S; Giannetta L; Cerea G; Schiavetto I; Bencardino K; Funaioli C; Ricotta R; Cipani T; Schirru M; Gambi V; Palmeri L; Carlo-Stella G; Rusconi F; Di Bella S; Burrafato G; Cassingena A; Valtorta E; Lauricella C; Pazzi F; Gambaro A; Ghezzi S; Marrapese G; Tarenzi E; Veronese S; Truini M; Vanzulli A; Siena S
Target Oncol; 2017 Aug; 12(4):525-533. PubMed ID: 28669023
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
37. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
[TBL] [Abstract][Full Text] [Related]
38. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
39. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.
Ghidini M; Petrelli F; Hahne JC; De Giorgi A; Toppo L; Pizzo C; Ratti M; Barni S; Passalacqua R; Tomasello G
Med Oncol; 2017 Apr; 34(4):62. PubMed ID: 28315230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]